Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Allarity Therapeutics, Inc. - Common stock (NQ:ALLR)

0.9141 +0.0351 (+3.99%)
Streaming Delayed Price Updated: 12:58 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 154,846
Open 0.8717
Bid (Size) 0.9053 (1)
Ask (Size) 0.9255 (4)
Prev. Close 0.8790
Today's Range 0.8717 - 0.9400
52wk Range 0.6138 - 6.000
Shares Outstanding 365,173,471
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Stock Market Today: S&P 500, Nasdaq Futures Decline— Palo Alto, XP, Allarity Earnings In Focus
U.S. stock futures slipped on Monday following Friday's mixed moves. Futures of major benchmark indices were lower. 
Via Benzinga
Topics Stocks
Palo Alto Networks, Fabrinet And 3 Stocks To Watch Heading Into Monday
 
Via Benzinga

Performance

YTD
-17.6%
-17.6%
1 Month
-8.1%
-8.1%
3 Month
-14.2%
-14.2%
6 Month
-2.8%
-2.8%
1 Year
-81.8%
-81.8%

More News

Read More
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships
From Allarity Therapeutics, Inc.
Via GlobeNewswire
This MongoDB Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Changes to Board of Directors
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
From Allarity Therapeutics, Inc.
Via GlobeNewswire
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert
Via Benzinga
Topics World Trade
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday
Via Benzinga
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
From Allarity Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission
From Allarity Therapeutics, Inc.
Via GlobeNewswire
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week
Via Stocktwits
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program
From Allarity Therapeutics, Inc.
Via GlobeNewswire
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit
From Allarity Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Allarity Therapeutics, Inc. - Common stock publicly traded?
Yes, Allarity Therapeutics, Inc. - Common stock is publicly traded.
What exchange does Allarity Therapeutics, Inc. - Common stock trade on?
Allarity Therapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allarity Therapeutics, Inc. - Common stock?
The ticker symbol for Allarity Therapeutics, Inc. - Common stock is ALLR on the Nasdaq Stock Market
What is the current price of Allarity Therapeutics, Inc. - Common stock?
The current price of Allarity Therapeutics, Inc. - Common stock is 0.9141
When was Allarity Therapeutics, Inc. - Common stock last traded?
The last trade of Allarity Therapeutics, Inc. - Common stock was at 08/22/25 12:58 PM ET
What is the market capitalization of Allarity Therapeutics, Inc. - Common stock?
The market capitalization of Allarity Therapeutics, Inc. - Common stock is 333.81M
How many shares of Allarity Therapeutics, Inc. - Common stock are outstanding?
Allarity Therapeutics, Inc. - Common stock has 334M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.